Technologies that enable targeted manipulation of epigenetic marks could be used to precisely control cell phenotype or interrogate the relationship between the epigenome and transcriptional control. Here we describe a programmable, CRISPR-Cas9-based acetyltransferase consisting of the nuclease-null dCas9 protein fused to the catalytic core of the human acetyltransferase p300. The fusion protein catalyzes acetylation of histone H3 lysine 27 at its target sites, leading to robust transcriptional activation of target genes from promoters and both proximal and distal enhancers. Gene activation by the targeted acetyltransferase was highly specific across the genome. In contrast to previous dCas9-based activators, the acetyltransferase activates genes from enhancer regions and with an individual guide RNA. We also show that the core p300 domain can be fused to other programmable DNA-binding proteins. These results support targeted acetylation as a causal mechanism of transactivation and provide a robust tool for manipulating gene regulation.
A r t i c l e s A central challenge in functional genomics is to develop technologies for precise manipulation of individual loci. Projects such as ENCODE 1 and the Roadmap Epigenomics Project 2 have identified millions of epigenetic marks across the human genome for many human cell types and tissues. Studying the function of those marks, however, has been largely limited to determining statistical associations with gene expression. Technologies for targeted direct manipulation of epigenetic marks are needed to transform association-based findings into mechanistic principles of gene regulation. Such advances have the potential to benefit human health by enabling new platforms for disease modeling, drug screening, gene therapy and cell lineage specification. Smallmolecule drugs, such as inhibitors of histone deacetylases or DNA methyltransferases, alter the epigenome and transcriptome globally and cannot target individual loci. Fusions of epigenome-modifying enzymes to programmable DNA-binding proteins, such as zinc finger proteins and transcription activator-like effectors (TALEs), are effective at achieving targeted DNA methylation and hydroxymethylation, and histone demethylation, methylation and deacetylation [3] [4] [5] [6] [7] [8] . However, a method for targeted histone acetylation, which is strongly associated with active gene regulatory elements and enhancers, has not been described. In addition, the CRISPR-Cas9 (clustered, regularly interspaced, short palindromic repeat-CRISPR-associated protein) genome engineering tool 9, 10 , which can be readily targeted to loci of interest, has not yet been extensively applied to epigenome editing.
The Cas9 nuclease can be directed to specific genomic loci using complementarity between an engineered guide RNA (gRNA) and the target site [11] [12] [13] . The enzymatic activity of the Cas9 nuclease can be abolished by mutation of the RuvC and HNH domains, generating the nuclease-null deactivated Cas9 (dCas9) 12 . Fused to repression domains, such as the KRAB domain, or to activation domains, such as oligomers of the herpes simplex viral protein 16 (VP16), dCas9 can function as a synthetic transcriptional regulator [14] [15] [16] [17] [18] [19] [20] [21] . However, dCas9 activators have limitations, including the need for multiple activation domains 14, 20, 22, 23 or combinations of gRNAs 16, 17 to achieve high levels of gene induction by synergistic effects between activation domains 24, 25 . Moreover, the activator domains used in these engineered transcriptional factors, such as the VP16 tetramer VP64 (ref. 26) , act as scaffolds for recruiting multiple components of the preinitiation complex 27, 28 and do not enzymatically modulate the chromatin state directly. This indirect method of epigenetic remodeling does not allow testing of the role of specific epigenetic marks and may not be as potent as direct alteration of epigenetic states. We hypothesized that recruitment of an acetyltransferase by dCas9 to a genomic target site would directly modulate the epigenome and activate nearby gene expression. To this end, we designed a fusion protein of dCas9 with the catalytic histone acetyltransferase (HAT) core domain of the human E1A-associated protein p300 (ref. 29 ), a highly conserved acetyltransferase involved in a wide range of cellular processes 30,31 . epigenome editing by a crisPr-cas9-based acetyltransferase activates genes from promoters and enhancers A r t i c l e s We demonstrate that this easily programmable approach facilitates robust control of the epigenome and downstream gene expression.
RESULTS

A dCas9 fusion to the p300 HAT domain activates target genes
We fused the full-length human p300 protein to dCas9 (dCas9 FLp300 ; Fig. 1a,b ) and assayed its capacity for transactivation by transient co-transfection of human HEK293T cells with four gRNAs targeting the endogenous promoters of IL1RN, MYOD (also known as MYOD1) and OCT4 (also known as POU5F1; Fig. 1c ). We used a combination of four gRNAs targeting each promoter based on our and others' previous observations that multiple gRNAs at a single promoter are necessary for robust gene activation [14] [15] [16] [17] [18] [19] [20] [21] [22] . dCas9 FLp300 was well-expressed and induced modest activation above background compared to the canonical dCas9 activator fused to the VP64 acidic activation domain (dCas9 VP64 ; Figs. 1a-c). The full-length p300 protein is a promiscuous acetyltransferase, which interacts with a multitude of endogenous proteins, largely through its termini 29, 31 .
To mitigate these interactions we isolated the contiguous region of full-length p300 (2,414 amino acids) solely required for inherent HAT activity (amino acids 1,048-1,664), known as the p300 HAT core domain (p300 Core) 29 . When fused to the C terminus of dCas9 (dCas9 p300 Core ; Fig. 1a,b ) the p300 Core domain induced high levels of transcription from endogenous gRNA-targeted promoters ( Fig. 1c) . When targeted to the IL1RN and MYOD promoters, the dCas9 p300 Core fusion displayed significantly higher levels of transactivation than dCas9 VP64 (P = 0.0124 and 0.0394, respectively; Fig. 1c ). These dCas9-effector fusion proteins were expressed at similar levels ( Fig. 1b and Supplementary Fig. 1 ) indicating that the observed differences reflect the distinct transactivation capacity of each construct. In addition, no changes to target gene expression were observed when the effector fusions were transfected without gRNAs ( Supplementary  Fig. 2 ). To confirm that the p300 Core acetyltransferase activity was responsible for gene transactivation using the dCas9 p300 Core fusion, we screened a panel of dCas9 p300 Core HAT-domain mutant fusion proteins ( Supplementary Fig. 1 ) 29 . A single inactivating amino acid substitution within the HAT core domain (WT residue D1399 of full-length p300) of dCas9 p300 Core (dCas9 p300 Core (D1399Y) ; Fig. 1a ) abolished the transactivation capacity of the fusion protein ( Fig. 1c) , demonstrating that intact p300 Core acetyltransferase activity was required for dCas9 p300 Core -mediated transactivation. dCas9 p300 Core activates genes from proximal and distal enhancers Although there are many published examples of genes being activated with engineered transcription factors targeted to promoters, inducing gene expression from other distal regulatory elements has been limited, particularly for dCas9-based activators [32] [33] [34] [35] . Given the role and localization of p300 at endogenous enhancers 36, 37 , we hypothesized that the dCas9 p300 Core would effectively induce transcription from distal regulatory regions with appropriately targeted gRNAs. We targeted the distal regulatory region (DRR) and core enhancer (CE) of the human MYOD locus 38 through co-transfection of four gRNAs targeted to each region and either dCas9 VP64 or dCas9 p300 Core ( Fig. 2a ). Compared to a mock-transfected control, dCas9 VP64 did not lead to any induction when targeted to the MYOD DRR or CE region. In contrast, dCas9 p300 Core induced significant transcription when targeted to either MYOD regulatory element with corresponding gRNAs (P = 0.0115 and 0.0009 for the CE and DRR regions, respectively). We also targeted the upstream proximal (PE) and distal enhancer (DE) regions of human OCT4 (ref. 39 ) by co-transfection of six gRNAs and either dCas9 VP64 or dCas9 p300 Core (Fig. 2b) . dCas9 p300 Core induced significant transcription from these regions (P ≤ 0.0001 and P = 0.003 for the DE and PE, respectively), whereas dCas9 VP64 was unable to activate OCT4 above background levels when targeted to either the PE or DE regions.
The well-characterized mammalian β-globin locus control region (LCR) orchestrates transcription of the downstream hemoglobin genes; hemoglobin epsilon 1 (HBE, also known as HBE1, from ~11 kb), hemoglobin gamma 1 and 2 (HBG, also known as HBG1, from ~30 kb), hemoglobin delta (HBD, from ~46 kb) and hemoglobin beta (HBB, from ~54 kb) ( Fig. 2c) 35, 40 . DNase hypersensitive sites within the β-globin LCR serve as docking sites for transcriptional and chromatin modifiers, including p300 (ref. 41) , which coordinate distal target gene expression. We designed four gRNAs targeting the DNase hypersensitive site 2 within the LCR enhancer region (HS2 enhancer). These four HS2-targeted gRNAs were co-transfected with dCas9, dCas9 VP64 , dCas9 p300 Core or α-FLAG 
npg
A r t i c l e s dCas9 p300 Core (D1399Y) , and the resulting mRNA production from HBE, HBG, HBD and HBB was assayed ( Fig. 2c) . dCas9, dCas9 VP64 and dCas9 p300 Core (D1399Y) did not transactivate any downstream genes when targeted to the HS2 enhancer. In contrast, targeting of dCas9 p300 Core to the HS2 enhancer led to significant expression of the downstream HBE, HBG and HBD genes (P ≤ 0.0001, 0.0056, and 0.0003 between dCas9 p300 Core and mock-transfected cells for HBE, HBG and HBD, respectively). Overall, HBD and HBE appeared relatively less responsive to synthetic p300 Core-mediated activation from the HS2 enhancer; a finding consistent with lower rates of general transcription from these two genes across several cell lines ( Supplementary  Fig. 3 ). Nevertheless, with the exception of the most distal HBB gene, dCas9 p300 Core activated transcription from downstream genes when targeted to all characterized enhancer regions assayed, a capability not observed for dCas9 VP64 . Together, these results demonstrate that dCas9 p300 Core is a potent programmable transcription factor that can be used to regulate gene expression from a variety of promoterproximal and promoter-distal locations.
Gene activation by dCas9 p300 Core is highly specific Recent reports indicate that dCas9 may have widespread off-target binding events in mammalian cells in combination with some gRNAs 42, 43 , which could potentially lead to off-target changes in gene expression. To assess the transcriptional specificity of the dCas9 p300 Core fusion protein we performed transcriptome profiling by RNAseq in cells co-transfected with four IL1RN-targeted gRNAs and either dCas9, dCas9 VP64 , dCas9 p300 Core or dCas9 p300 Core (D1399Y) . Genome-wide transcriptional changes were compared between The dCas9 p300 Core fusion protein activates transcription of endogenous genes from distal enhancer regions. (a) Relative MYOD mRNA production in cells co-transfected with a pool of gRNAs targeted to either the proximal or distal regulatory regions and dCas9 VP64 or dCas9 p300 Core ; promoter data from Figure 1c (Tukey-test, *P < 0.05 compared to mock-transfected cells; Tukey test †P < 0.05 between dCas9 p300 Core and dCas9 VP64 , n = 3 independent experiments; error bars, s.e.m.). The human MYOD locus is schematically depicted with corresponding gRNA locations in red. CE, MyoD core enhancer; DRR, MyoD distal regulatory region. (b) Relative OCT4 mRNA production in cells co-transfected with a pool of gRNAs targeted to the proximal and distal regulatory regions and dCas9 VP64 or dCas9 p300 Core ; promoter data from Figure 1c 
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A r t i c l e s dCas9 with no fused effector domain and either dCas9 VP64 , dCas9 p300 Core or dCas9 p300 Core (D1399Y) (Fig. 3) . Whereas both dCas9 VP64 and dCas9 p300 Core upregulated all four IL1RN isoforms, only the effects of dCas9 p300 Core reached genome-wide significance (Fig. 3a,b and Supplementary Table 1 ; P = 4.9 × 10 −4 to 2.7 × 10 −3 for dCas9 VP64 ; P = 1.5 × 10 −19 to 4.9 × 10 −17 for dCas9 p300 Core ). In contrast, dCas9 p300 Core (D1399Y) did not significantly induce any IL1RN expression ( Fig. 3c ; P > 0.5 for all four IL1RN isoforms). Comparative analysis to dCas9 revealed limited dCas9 p300 Core off-target gene induction, with only two transcripts induced significantly above background at a false discovery rate (FDR) < 5%: KDR (FDR = 1.4 × 10 −3 ) and FAM49A (FDR = 0.04) ( Fig. 3b and Supplementary Table 1 ). We also found increased expression of p300 mRNA in cells transfected with dCas9 p300 Core and dCas9 p300 Core (D1399Y) . This finding is most likely explained by RNA-seq reads mapping to mRNA from the transiently transfected p300 core fusion domains. Thus the dCas9 p300 Core fusion displayed high genome-wide targeted transcriptional specificity and robust gene induction of all four targeted IL1RN isoforms.
dCas9 p300 Core acetylates H3K27 at enhancers and promoters Activity of regulatory elements correlates with covalent histone modifications, such as acetylation and methylation 1, 2 . Of those histone modifications, acetylation of lysine 27 on histone H3 (H3K27ac) is one of the most widely documented indicators of enhancer activity [29] [30] [31] 36, 37 . Acetylation of H3K27 is catalyzed by p300 and is also correlated with endogenous p300 binding profiles 36, 37 . Therefore, we used H3K27ac enrichment as a measurement of relative dCas9 p300 Core -mediated acetylation at the genomic target site.
To quantify targeted H3K27 acetylation by dCas9 p300 Core , we performed chromatin immunoprecipitation with an anti-H3K27ac antibody followed by quantitative PCR (ChIP-qPCR) in HEK293T cells co-transfected with four HS2 enhancer-targeted gRNAs and either dCas9, dCas9 VP64 , dCas9 p300 Core or dCas9 p300 Core (D1399Y) (Fig. 4) .
We analyzed three amplicons at or around the target site in the HS2 enhancer or within the promoter regions of the HBE and HBG genes (Fig. 4a) . Notably, H3K27ac is enriched in each of these regions in the human K562 erythroid cell line, which has a high level of globin gene expression ( Fig. 4a) . We observed significant H3K27ac enrichment at the HS2 enhancer target locus compared to treatment with dCas9 in both the dCas9 VP64 (P = 0.0056 for ChIP Region 1 and P = 0.0029 for ChIP Region 3) and dCas9 p300 Core (P = 0.0013 for ChIP Region 1 and P = 0.0069 for ChIP Region 3) co-transfected samples (Fig. 4b) . A similar trend of H3K27ac enrichment was also observed when targeting the IL1RN promoter with dCas9 VP64 or dCas9 p300 Core (Supplementary Fig. 4) . In contrast to these increases in H3K27ac at the target sites by both dCas9 VP64 and dCas9 p300 Core , robust enrichment in H3K27ac at the HS2-regulated HBE and HBG promoters was observed only with dCas9 p300 Core treatment (Fig. 4c,d) . Together these results demonstrate that dCas9 p300 Core uniquely catalyzes H3K27ac enrichment at gRNA-targeted loci and at enhancer-targeted distal promoters. Therefore, the acetylation established by dCas9 p300 Core at HS2 may catalyze enhancer activity in a manner distinct from direct recruitment of preinitiation complex components by dCas9 VP64 (refs. 27,28), as indicated by the distal activation of the HBE, HBG A r t i c l e s and HBD genes from the HS2 enhancer by dCas9 p300 Core but not by dCas9 VP64 (Fig. 2c and Supplementary Fig. 3 ).
dCas9 p300 Core activates genes with a single gRNA Robust transactivation using dCas9-effector fusion proteins currently relies upon the application of multiple gRNAs, multiple effector domains or both [14] [15] [16] [17] [18] [19] [20] [21] [22] 24, 25 . Transcriptional activation could be simplified with the use of single gRNAs in tandem with a single dCas9-effector fusion. This would also facilitate multiplexing distinct target genes and the incorporation of additional functionalities into the system. We compared the transactivation potential of dCas9 p300 Core with single gRNAs and four pooled gRNAs targeting the IL1RN, MYOD and OCT4 promoters ( Fig. 5a-c) . Substantial activation was observed upon co-transfection of the dCas9 p300 Core and a single gRNA for each promoter tested. For the IL1RN and MYOD promoters, there was no significant difference between the pooled gRNAs and the best individual gRNA ( Fig. 5a-b; IL1RN gRNA "C", P = 0.78; MYOD gRNA "D", P = 0.26). Although activation of the OCT4 promoter produced additive effects when four gRNAs were pooled with dCas9 p300 Core , the most potent single gRNA (gRNA "D") induced a statistically equivalent amount of gene expression to that observed upon co-transfection of dCas9 VP64 with an equimolar pool of all four promoter gRNAs (P = 0.73; Fig. 5c ). Compared to dCas9 p300 Core , gene activation with dCas9 VP64 and single gRNAs was substantially lower. Also, in contrast to dCas9 p300 Core , dCas9 VP64 demonstrated synergistic effects with combinations of gRNAs in every case (Fig. 5a-c) , as reported previously 16, 17 . Based on the transactivation ability of dCas9 p300 Core at enhancer regions and with single gRNAs at promoter regions, we hypothesized that dCas9 p300 Core might also be able to transactivate enhancers by means of a single targeted gRNA. We tested the MYOD (DRR and CE), OCT4 (PE and DE) and HS2 enhancer regions with equimolar concentrations of pooled or individual gRNAs ( Fig. 5d-g) . For both MYOD enhancer regions, co-transfection of dCas9 p300 Core and a single enhancer-targeting gRNA was sufficient to activate gene expression to levels similar to cells co-transfected with dCas9 p300 Core and the four pooled enhancer gRNAs (Fig. 5d) . Similarly, OCT4 gene expression was activated from the PE through dCas9 p300 Core localization with a single gRNA to similar levels as dCas9 p300 Core localized with a pool of six PE-targeted gRNAs (Fig. 5e) . dCas9 p300 Core -mediated induction of OCT4 from the DE (Fig. 5e) and HBE and HBG genes from the HS2 enhancer ( Fig. 5f,g) showed increased expression with the pooled gRNAs relative to single gRNAs. Nevertheless, there was activation of target gene expression above control for several single gRNAs at these enhancers ( Fig. 5e-g) .
The p300 HAT domain is portable to other DNA-binding proteins
The dCas9-gRNA system from Streptococcus pyogenes has been widely adopted due to its robust, versatile and easily programmable properties 9, 10 . However, several other programmable DNA-binding proteins are also under development for various applications and may be preferable for particular applications, including orthogonal dCas9 systems from other species 44 , TALEs and zinc finger proteins. To determine if the p300 Core HAT domain was portable to these other systems, we created fusions to dCas9 from Neisseria meningitidis (Nm-dCas9) 44 , four different TALEs targeting the IL1RN promoter 24 and a zinc finger protein targeting ICAM1 (Fig. 6) . Co (f,g) Relative HBE (f) or HBG (g) mRNA production in cells co-transfected with dCas9 p300 Core and the indicated gRNAs targeted to the HS2 enhancer (Tukey test between dCas9 p300 Core and single HS2 gRNAs compared to mock-transfected cells, *P < 0.05; Tukey test among dCas9 p300 Core and HS2 single gRNAs compared to All, †P < 0.05, n = 3 independent experiments; error bars, s.e.m.). HS2, β-globin locus control region hypersensitive site 2; n.s., not significant using Tukey test.
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A r t i c l e s to significant gene induction compared to mock-transfected controls (P = 0.038 and 0.0141 for HBE and HBG, respectively) ( Fig. 6b,c) . When co-transfected with five Nm-gRNAs targeted to the HS2 enhancer, Nm-dCas9 p300 Core also significantly activated the distal HBE and HBG globin genes compared to mock-transfected controls (P = 0.0192 and P = 0.0323, respectively) ( Fig. 6d,e ). Similar to dCas9 p300 Core , Nm-dCas9 p300 Core activated gene expression from promoters and the HS2 enhancer with a single gRNA. Nm-dCas9 VP64 displayed negligible capacity to transactivate HBE or HBG regardless of localization to promoter regions or to the HS2 enhancer either with single or multiple gRNAs ( Fig. 6b-e ). Transfection of the expression plasmids for a combination of four TALE p300 Core fusion proteins targeted to the IL1RN promoter (IL1RN TALE p300 Core ) also activated downstream gene expression, although to a lesser extent than four corresponding TALE VP64 fusions (IL1RN TALE VP64 ) ( Fig. 6f,g) . However, single p300 Core effectors were much more potent than single VP64 domains when fused to IL1RN TALEs. Interestingly, dCas9 p300 Core directed to any single binding site generated comparable IL1RN expression relative to single or pooled IL1RN TALE effectors, and direct comparisons suggest that dCas9 may be a more robust activator than TALEs when fused to the larger p300 Core fusion domain (Supplementary Fig. 5) . Finally, the ZF p300 Core fusion targeted to the ICAM1 promoter (ICAM1 ZF p300 Core ) also activated its target gene relative to control and at a similar level as ZF VP64 (ICAM1 ZF VP64 ) (Fig. 6h,i) . The versatility of the p300 Core fusion with multiple targeting domains is evidence that this is a robust approach for targeted acetylation and gene regulation. The various p300 core fusion proteins were expressed well, as determined by western blot analysis (Supplementary Fig. 6 ), but differences in p300 Core activity between different fusion proteins could be attributable to binding affinity or protein folding.
DISCUSSION
These results establish the dCas9 p300 Core fusion protein as a potent and easily programmable tool to synthetically manipulate acetylation at targeted endogenous loci, leading to regulation of proximal and distal enhancer-regulated genes. The intrinsic p300 Core acetyltransferase activity is crucial for this efficacy, as demonstrated by the consistent lack of chromatin modification and transactivation potential of the dCas9 p300 Core (D1399Y) acetyltransferase-null mutant (Figs. 1c,  2c and 4b-d and Supplementary Fig. 1) . Fusion of the catalytic core domain of p300 to dCas9 resulted in substantially higher transactivation of downstream genes than the direct fusion of full-length p300 protein despite robust protein expression ( Fig. 1b,c) . This may be due to differences in protein structure and function or interactions with other cellular proteins, suggesting that isolation of catalytic core regions is a useful strategy for future programmable epigenome editing tools. The dCas9 p300 Core fusion protein also had an increased transactivation capacity relative to dCas9 VP64 (Figs. 1c, 2, 3 and 5) , including in the context of the Nm-dCas9 scaffold ( Fig. 6b-e ). This was especially evident at distal enhancer regions, at which dCas9 VP64 displayed little, if any, measurable downstream transcriptional activity (Figs. 2 and 6d,e ). In addition, the dCas9 p300 Core displayed precise and robust genome-wide transcriptional specificity ( Fig. 3 and Supplementary Fig. 2) .
The observation that targeted acetylation is sufficient for gene activation at an endogenous locus and enhancer is a notable finding of our study. Although it is possible that activation or recruitment of other co-factors is involved in the targeted dCas9 p300 Coremediated epigenomic control, only dCas9 p300 Core and not VP64 was capable of potent transcriptional activation and co-enrichment of acetylation at promoters targeted by the epigenetically modified enhancer ( Figs. 2c and 3c,d and Supplementary Fig. 3) 
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A r t i c l e s effector domains have different modes of activity; whereas p300 has inherent acetyltransferase activity 29, 30 , VP64 relies upon sequential recruitment of co-factors, including endogenous p300, for HAT activity at sites of transactivation 27, 28 . Thus, our results support a model in which acetylation is a sufficient step in activating enhancer activity, at least at the loci tested here. The unique activity of dCas9 p300 Core supports its use in elucidating key steps of gene regulation, including dissection of the interplay between the epigenome, regulatory element activity and gene regulation. For example, the GATA1 transcription factor that is essential for globin gene expression in erythroid cells 45 is not expressed in the HEK293T cells used in this study 16 . The observed potent activation of globin gene expression by dCas9 p300 Core -mediated acetylation in the absence of GATA1 suggests that the acetylation at the enhancer occurs downstream of GATA1 but upstream of globin gene activation in erythroid cells. Notably, the greater transactivation potency of direct acetylation by dCas9 p300 Core relative to dCas9 VP64 suggests that acetylation of additional factors at the target site may also play a role, and this should be a subject of future investigation. dCas9 p300 Core is more potent than existing engineered transcription factors made with single activator domains. Although synergy among other synthetic transcriptional activators, including dCas9 VP64 (refs. 8,15-17,19-22,24,25) , has been widely observed, the p300 Core effector domain did not display similar synergy with either additional gRNAs or TALEs (Figs. 5 and 6 and Supplementary Figs. 3 and 5 ) or in combination with VP64 ( Supplementary Fig. 7) . Moreover, the p300 Core effector was capable of robustly activating gene expression through a single gRNA at promoters and characterized enhancers (Figs. 5  and 6 and Supplementary Fig. 3) . This effector was also capable of potent gene activation when targeted by a single TALE recognition site ( Fig. 6  and Supplementary Fig. 5) . Notably, certain loci appear to be less responsive to transactivation by the localization of a single dCas9 p300 Core effector to a corresponding regulatory region ( Fig. 5e-g and Supplementary Fig. 3 ). This does not appear to be related to chromatin accessibility based on ENCODE data (Supplementary Fig. 8 ), but may be related to transcription factor occupancy or competition (including endogenous p300; Supplementary Figs. 3 and 8) , gRNA and genetic composition 46 , transcription start site proximity 14 , and/or the underlying local epigenetic circuitry, none of which are mutually exclusive. These factors are relevant to the function of all programmable DNA-binding proteins and their effects may be mitigated by the use of optimal gRNAs.
Our results indicate a causal relationship between directed acetylation and subsequent target-gene activation. The technology affords the ability to synthetically transactivate distal genes from putative and known regulatory regions and simplifies transactivation by the application of a single programmable effector and single target site. These capabilities could be important in enabling genome-wide screens of regulatory element activity and in multiplexing to target several promoters and/or enhancers simultaneously 14, 20, 47 . Furthermore combining dCas9 p300 Core with light-inducible 7, 48 or chemically inducible 49 control would permit dynamic control of gene activation in space and time. The ability to target the p300 Core domain with orthogonal dCas9s, TALEs and zinc finger proteins should facilitate studies of independent targeting of particular effector functions to distinct loci ( Fig. 5 and Supplementary Fig. 3 ). This could include multiplexing of various activators, repressors and epigenetic modifiers to precisely control cell phenotype 23, 33, 50 or decipher complex networks of gene regulation. In addition, the mammalian origin of p300 may provide advantages over virally derived effector domains for in vivo applications by minimizing potential immunogenicity.
The synthetic control of transcription and chromatin remodeling is a critical component of cellular engineering. dCas9 p300 Core takes advantage of the simple programmability of the CRISPR-Cas9 system to target acetyltransferase activity and complements other recently described epigenetic editing tools, including fusions of demethylases, methyltransferases and deacetylases [3] [4] [5] [6] [7] to generate a more complete set of epigenome editing tools.
METHODS
Methods and any associated references are available in the online version of the paper.
